The September quarter is the first quarter in which the Company’s cash revenues exclusively comprised the
sale of cannabinoid products under the Australian special access scheme (‘SAS’). IHL previously reported a
record period of sales in the June quarter, however, that figure also included cash inflows from a dental
devices business that was sold on the 30th of June.
General discussion, page-1984
-
- There are more pages in this discussion • 18,459 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)